Sökning: "Clinical drug development"

Visar resultat 11 - 15 av 461 avhandlingar innehållade orden Clinical drug development.

1. 11. Development and application of new methods for anticancer drug discovery and early evaluation

   Författare :Sumeer Dhar; Uppsala universitet; []
   Nyckelord :Medical sciences; Drug development; tumor cell lines; cytotoxic drugs; neural network; MEDICIN OCH VÅRD; MEDICINE; MEDICIN; klinisk farmakologi; Clinical Pharmacology;

   Sammanfattning : A non-clonogenic assay using the redox dye Alamar Blue and primary human tumor cells (PHTC) from patients and human tumor cell lines (HTCL) was established for rapid screening and evaluation of anticancer drugs. PHTC cultures from chronic lymphocytic leukemia (CLL) and ovarian carcinoma (Ovca) were compared with renal carcinoma (ACHN) and lymphocytic (CCRF-CEM) HTLCs in response to 63 toxic or non-toxic compounds. LÄS MER

3. 12. Methodological aspects and usefulness of Quantitative Sensory Testing in early small fiber polyneuropathy : a clinical study in Swedish hereditary transthyretin amyloidosis patients

   Författare :Victoria Heldestad; Erik Nordh; Ole Suhr; Göran Solders; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Amyloidosis; cold thresholds; heart rate variability; method-of-limits; quantitative sensory testing; transthyretine; warm thresholds; Clinical Neurophysiology; klinisk neurofysiologi;

   Sammanfattning : Generalised polyneuropathy (PNP) is a common cause to neurological impairment, and may be an early symptom of a severe systemic disease. One such illness is hereditary transthyretin (TTR) amyloidosis (ATTR), a progressive fatal disorder caused by a mutation on the TTR gene. LÄS MER

4. 13. Application of In Vitro Chemosensitivity Testing for Evaluation of New Cytotoxic Drugs in Chronic Lymphocytic Leukaemia

   Författare :Anna Åleskog; Jan Liliemark; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Clinical drug development; chronic lymphocytic leukaemia; cytotoxicity; in vitro assay; cytotoxic drug development; CHS 828; IgVH mutation status; Klinisk läkemedelsutveckling; Pharmaceutical chemistry; Läkemedelskemi; Clinical Pharmacology; klinisk farmakologi;

   Sammanfattning : Despite major advances in the understanding of the biology of chronic lymphocytic leukaemia (CLL), progress in improving its treatment has been limited and it still remains an incurable disorder. In the present research, we have performed in vitro drug sensitivity testing of primary CLL cells for preclinical evaluation of cytotoxic drugs, using the fluorometric microculture cytotoxicity assay (FMCA). LÄS MER

5. 14. Prostate Cancer; Metabolic Risk Factors, Drug Utilisation, Adverse Drug Reactions

   Författare :Birgitta Grundmark; Lars Holmberg; Björn Zethelius; Gunnar Engström; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Prostate cancer; Epidemiology; Pharmacoepidemiology; Metabolic Syndrome; Selenium; Smoking; hOGG1; MnSOD; Competing Risk; Adherence; Persistance; Medical Possession Ratio; MPR; Signal Detection; PRR; proportional reporting ratio; ULSAM; PcBaSE; EudraVigilance; SPDR; Swedish Prescribe Drug Registry; NPCR; National Prostate Cancer Registry; SDR; Signal; disproportionality analysis; PRR-TA; EudraVigilance; Epidemiology; Epidemiologi; Kirurgi; särskilt urologi; Urology; Oncology; Onkologi; Geriatrics; Geriatrik;

   Sammanfattning : Increased possibilities during the last decades for early detection of prostate cancer have sparked research on preventable or treatable risk factors and on improvements in therapy. Treatments of the disease still entail significant side effects potentially affecting men during the rest of their lives. LÄS MER

7. 15. Safety and Efficacy Modelling in Anti-Diabetic Drug Development

   Författare :Bengt Hamrén; Mats O Karlsson; Eric Snoeck; Uppsala universitet; []
   Nyckelord :Pharmaceutical biosciences; pharmacokinetic; pharmacodynamic; mechanism-based; modelling; type 2 diabetes mellitus; tesaglitazar; PPAR; drug development; NONMEM; Farmaceutisk biovetenskap;

   Sammanfattning : A central aim in drug development is to ensure that the new drug is efficacious and safe in the intended patient population. Mathematical models describing the pharmacokinetic-pharmacodynamic (PK-PD) properties of a drug are valuable to increase the knowledge about drug effects and disease and can be used to inform decisions. LÄS MER